The global point-of-care (POC) drug abuse testing market is evolving rapidly as the demand for immediate and reliable testing solutions grows across healthcare, law enforcement, and workplace environments. Advancements in portable testing technologies have significantly enhanced the speed and accuracy of detecting substances, making these devices essential tools for early intervention and effective monitoring. In addition, increased regulatory measures and heightened awareness about substance abuse have further propelled market growth, as organizations seek efficient ways to enforce safety and compliance standards. Although challenges such as ensuring test accuracy and minimizing false positives persist, ongoing innovation and strategic investments continue to drive market expansion, paving the way for broader application and improved public health outcomes.
Global Point-of-Care (POC) Drug Abuse Testing Market is valued at USD 1.41 billion in 2023and is expected to reach USD 2.01 billion by 2031, with a growing CAGR of 4.7% during the forecast period 2024 to 2031.
To know more, visit https://www.databridgemarketresearch.com/reports/global-point-of-care-poc-drug-abuse-testing-market
Below are the Top Point-of-Care (POC) Drug Abuse Testing Companies with a Significant Market Share:
|
Rank |
Company |
Overview |
Product Portfolio |
Sales Geographical Coverage |
Developments |
|
1. |
Abbott |
Abbott is a global healthcare company specializing in diagnostics, medical devices, nutrition, and pharmaceuticals. It is a leader in point-of-care (POC) drug testing, offering rapid diagnostic solutions under its Abbott Rapid Diagnostics division. Key products include Abbott’s Panbio and i-STAT systems, which provide fast and accurate drug screening. Abbott’s strong focus on innovation and global reach make it a dominant player in the POC drug abuse testing market. |
|
North America, Middle East and Africa, Asia-Pacific, and Europe |
In August 2024, Abbott announced a global partnership with Medtronic on August 7, 2024, to integrate Abbott's advanced FreeStyle Libre continuous glucose monitoring (CGM) technology with Medtronic's insulin delivery systems. This collaboration aimed to enable automatic insulin adjustments and improve diabetes management, benefiting over 11 million people worldwide. Financial terms were undisclosed. |
|
2. |
Siemens Healthineers |
Quest Diagnostics is a leading provider of diagnostic testing services, including drug abuse screening and toxicology testing. It offers rapid drug screening solutions for workplaces, healthcare providers, and law enforcement agencies. Quest’s Express Results Online and Drug Testing Panels provide fast, reliable, and accessible drug abuse testing. The company has a broad network of diagnostic laboratories and a strong POC testing infrastructure. |
|
America, Middle East and Africa, Asia-Pacific, and Europe |
In May 2024, Siemens Healthineers announces USD 270m Oxford facility, the UK’s first major production site for new MRI cooling technology. The Oxford facility boosts Siemens Healthineers' production capabilities, strengthens market position, and supports global expansion, enhancing their leadership in MRI technology and increasing revenue potential. |
|
3. |
Quest Diagnostics |
Quest Diagnostics is a leading provider of diagnostic testing services, including drug abuse screening and toxicology testing. It offers rapid drug screening solutions for workplaces, healthcare providers, and law enforcement agencies. Quest’s Express Results Online and Drug Testing Panels provide fast, reliable, and accessible drug abuse testing. The company has a broad network of diagnostic laboratories and a strong POC testing infrastructure. |
|
North America, Middle East and Africa, Asia-Pacific, and Europe |
|
|
4. |
Thermo Fisher Scientific |
Thermo Fisher Scientific is a global leader in scientific instruments, laboratory diagnostics, and biotechnology solutions. The company provides drug abuse testing kits, analyzers, and rapid screening tools for point-of-care applications. Its ToxSpec, DRI, and CEDIA drug testing solutions are widely used for workplace and forensic drug screening. Thermo Fisher’s strong R&D investments and global distribution network make it a key player in the POC drug testing market. |
|
North America, Middle East and Africa, Asia-Pacific, and Europe |
In November 2014, Thermo Fisher Scientific Inc. and Samsung Electronics Co., Ltd. announced a strategic partnership aimed at addressing the healthcare industry's need for improved point-of-care (POC) diagnostics. |
|
5. |
F. Hoffmann-La Roche Ltd |
Roche is a leading pharmaceutical and diagnostics company known for its innovative medical solutions. In POC drug abuse testing, Roche provides urine and blood-based rapid screening tests that detect a wide range of substances. The cobas and Accu-Chek systems help healthcare providers conduct accurate and quick drug screening. Roche's focus on automation and digital diagnostics strengthens its presence in the POC market. |
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe |
In February 2024, Roche entered into collaboration agreement with PathAI to expand digital pathology capabilities for companion diagnostics. The collaboration provides Roche with PathAI’s advanced AI technology for improving companion diagnostics. It ensures exclusive, tailored solutions and accelerates algorithm development while allowing Roche to continue developing its own diagnostics. |
Conclusion
The global point-of-care (POC) drug abuse testing market is set for continued growth, driven by the increasing need for fast, accurate, and accessible drug testing solutions across various sectors. As regulatory frameworks tighten and awareness of substance abuse rises, demand for reliable POC testing devices is expected to expand further. While challenges such as test accuracy and potential false positives remain, ongoing technological advancements and strategic investments are addressing these concerns. With a growing emphasis on workplace safety, law enforcement measures, and public health initiatives, the market will likely witness sustained innovation, improving the effectiveness and reach of drug abuse testing solutions worldwide.
